Neugebauer E, Lorenz W, Rixen D, Stinner B, Sauer S, Dietz W
Biochemical and Experimental Division, II, University of Cologne, Germany.
Crit Care Med. 1996 Oct;24(10):1670-7. doi: 10.1097/00003246-199610000-00012.
To determine if histamine release occurs in clinical sepsis.
Prospective, controlled, clinical study.
Interdisciplinary intensive care unit and trauma ward.
Sepsis was confirmed in 20 patients (test group) by the criteria of the Veterans Administration Systemic Sepsis Cooperative Study Group (1987) and was verified by positive blood culture. In addition, patients were scored by the Elebute and Stoner Sepsis Score (1983), as modified by Dionigi et al (1985). A concomitant control group consisted of 20 postoperative patients with non-life-threatening trauma to the extremities and without signs of local or systemic infection.
Observational study. Blood samples were collected for determination of plasma histamine concentrations in both groups at the time of study entry and on five succeeding days.
The patients were well matched, and the groups were not significantly different for all criteria known to influence histamine release. Comparison of the median values of each group on days 1 through 5 demonstrated significantly higher plasma histamine values in the test group on days 1 through 4, but these values were no longer significantly higher on day 5. While none of the nonseptic control patients achieved a plasma histamine concentration of > 1 ng/mL (the concentration of which was considered to be the pathologic cutoff point representing histamine release), these values (i.e., > 1 ng/ mL) were found in nine of 20 test group patients. In the test group, nonsurvivors (n = 9) had significantly higher plasma histamine concentrations than survivors (n = 11) throughout the whole study and eight of nine nonsurvivors showed a plasma histamine concentration of > 1 ng/mL. Correlation of plasma histamine concentrations on day 1 to sepsis severity (initial Sepsis Score) showed that all but one patient with a combined low Sepsis Score (< 20 points) and histamine concentration of < 1 ng/mL survived, while all patients with a Sepsis Score of > 20 points and histamine release (plasma histamine concentration of > 1 ng/mL) died.
Increased histamine concentrations were shown to be causally associated (contributory determinant) with sepsis.
确定临床脓毒症时是否会发生组胺释放。
前瞻性、对照临床研究。
跨学科重症监护病房和创伤病房。
根据退伍军人管理局系统性脓毒症协作研究组(1987年)的标准,20例患者(试验组)确诊为脓毒症,并经血培养阳性证实。此外,患者按照Dionigi等人(1985年)修改后的Elebute和Stoner脓毒症评分(1983年)进行评分。一个同期对照组由20例术后患者组成,这些患者四肢受到非危及生命的创伤,且无局部或全身感染迹象。
观察性研究。在研究开始时及随后五天,采集两组患者的血样以测定血浆组胺浓度。
患者匹配良好,两组在所有已知影响组胺释放的标准方面无显著差异。比较第1天至第5天每组的中位数,试验组在第1天至第4天的血浆组胺值显著更高,但在第5天这些值不再显著更高。非脓毒症对照组患者血浆组胺浓度均未达到>1 ng/mL(该浓度被认为是代表组胺释放的病理临界值),而试验组20例患者中有9例出现这些值(即>1 ng/mL)。试验组中,在整个研究过程中,非存活者(n = 9)的血浆组胺浓度显著高于存活者(n = 11),9例非存活者中有8例血浆组胺浓度>1 ng/mL。第1天血浆组胺浓度与脓毒症严重程度(初始脓毒症评分)的相关性显示,除1例脓毒症评分低(<20分)且组胺浓度<1 ng/mL的患者存活外,所有脓毒症评分>20分且有组胺释放(血浆组胺浓度>1 ng/mL)的患者均死亡。
组胺浓度升高被证明与脓毒症存在因果关联(促成决定因素)。